GBM is the most common and aggressive primary CNS malignancy with a median survival of 12-14 months. Less than 3% of GBM patients survive three years. Understanding the clinical profile along with the predictors for Long Term Survivors is of outstanding importance.
This study used IQVIA syndicated cross sectional surveys analysing retrospectively anonymized live patient-level data between January 2016 and September 2017 from EU5, Canada, Australia, Korea, China, Taiwan, Brazil and Mexico. We characterized patients who achieved at least 400 days (group 400) between their diagnosis and the start date of their latest therapy at the time they were surveyed. 370 patients correspond to group 400 from the collected population of 3,036. Due to methodological limitations for data collection, we will mainly focus our analysis on the clinical profile of group 400 without fully comparing them with the rest of the population.
Majority of patients in group 400 are relapsed (92.4%) with a mean of 791.7 ±780.6 days from diagnosis to relapse date (N = 342). 38% of patients are having an ECOG more than 2 at the moment of their current therapy and 67% have no comorbidities. The time to first chemotherapy has a mean value of 293.3 ±795.1 days) and the time to first surgery is 33.7 ±250.5 days. 57.0% of patients had one surgery with 70.8% of these patients having a total resection for their last surgery. In addition, the age of the patients was below 45 years for 33% for group 400 versus 20% for the bellow 400, which indicate a higher number of young patients in the group 400. We identified that Ratio male/female is relatively homogenous across both groups. The expression of mutant EGFRvIII was significantly lower (4.59%) in the 400 group compared with 16.84% in the bellow 400 group (P<.0001). MGMT promoter methylation was not significantly different (P = 0.3711).
GBM patients who reach 400 days between their diagnosis and the start date of last therapy are in majority patients who had relapsed and more likely to be younger, and show a lower percentage of non-mutated EGFRvIII. Of outmost clinical interest, it would be to predict what patients would pass from below 400 group to 400 days group.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.